<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945269</url>
  </required_header>
  <id_info>
    <org_study_id>2271.00</org_study_id>
    <secondary_id>NCI-2010-00738</secondary_id>
    <secondary_id>K12CA076930</secondary_id>
    <secondary_id>R21CA137647</secondary_id>
    <nct_id>NCT00945269</nct_id>
  </id_info>
  <brief_title>Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma</brief_title>
  <official_title>Phase I/II Study To Evaluate The Safety Of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following CD25 Lymphodepletion For Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor&#xD;
      cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white&#xD;
      blood cells to kill melanoma cells. Giving therapeutic autologous lymphocyte therapy together&#xD;
      with aldesleukin and denileukin diftitox may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving therapeutic autologous&#xD;
      lymphocytes together with aldesleukin and denileukin diftitox and to see how well it works in&#xD;
      treating patients with stage III-IV melanoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the safety of cellular adoptive immunotherapy in melanoma patients using autologous&#xD;
      CD8+ antigen-specific T-cell clones following CD25 lymphodepletion.&#xD;
&#xD;
      II. Determine the influence of CD25 lymphodepletion on the duration of in vivo persistence of&#xD;
      adoptively transferred CD8+ antigen-specific cytotoxic T-cell (CTL) clones.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the anti-tumor efficacy of cellular adoptive immunotherapy in melanoma patients&#xD;
      using autologous CD8+ antigen-specific T cell clones following CD25 lymphodepletion.&#xD;
&#xD;
      II. Evaluate the induction of T cells to non-targeted tumor-associated antigens&#xD;
      (antigen-spreading) following adoptive transfer of CD8+ antigen-specific CTL and CD25&#xD;
      lymphodepletion.&#xD;
&#xD;
      OUTLINE: This is a phase I study followed by a phase II study.&#xD;
&#xD;
      Patients receive autologous T-cell intravenously (IV) over 30-60 minutes on days 0 and 28 and&#xD;
      low-dose aldesleukin subcutaneously (SC) twice daily on days 0 to 13 and 28 to 41. Beginning&#xD;
      4-6 days before second T- cell infusion, patients receive denileukin diftitox IV over 30&#xD;
      minutes on days 1-3. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks, 8 weeks, and then&#xD;
      every 3 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer be&#xD;
    supporting clinical trials that utilize this drug.&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In vivo survival of CD8+ transferred T-clones</measure>
    <time_frame>Days +0, 1, 3, 7, 14, 22, 28, 29, 31, 35, 42, 49, 56, 63, 70, 77, 84</time_frame>
    <description>The design of this trial using the first infusion of CD8 T cells administered alone as a baseline for each patient permits intra-patient analysis using paired samples with increased statistical power.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage III Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <other_name>AL</other_name>
    <other_name>Autologous Lymphocytes</other_name>
    <other_name>autologous T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denileukin diftitox</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <other_name>DAB389 interleukin-2</other_name>
    <other_name>DAB389 interleukin-2 immunotoxin</other_name>
    <other_name>DAB389-IL2</other_name>
    <other_name>DABIL2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cellular adoptive immunotherapy)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological documentation of melanoma&#xD;
&#xD;
          -  Expression of human leukocyte antigen (HLA)-A2 or B44 as determined by HLA typing lab&#xD;
&#xD;
          -  Patients whose tumor expresses targeted antigen and restricting allele against which&#xD;
             CD8 T cell clones can be generated&#xD;
&#xD;
          -  Karnofsky Performance status of at least 80% and an expected survival of greater than&#xD;
             6 months&#xD;
&#xD;
          -  Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic&#xD;
             imaging (X-ray, computed tomography [CT] scan)&#xD;
&#xD;
          -  Normal cardiac stress test (treadmill, echocardiogram, or myocardial perfusion scan)&#xD;
             within 182 days prior to enrollment is required of patients with a history of cardiac&#xD;
             disease&#xD;
&#xD;
          -  Pulse &gt; 45 or &lt; 120&#xD;
&#xD;
          -  Weight &gt;= 45 kg&#xD;
&#xD;
          -  Temperature =&lt; 38C (&lt; 100.4 F)&#xD;
&#xD;
          -  White blood cells (WBC) &gt;= 3,000&#xD;
&#xD;
          -  Hematocrit (HCT) &gt;= 30%&#xD;
&#xD;
          -  Platelets &gt;= 100,000&#xD;
&#xD;
          -  Patients must be willing and able to discontinue the use of all antihypertensive&#xD;
             medications 24 hours prior to and during IL2 therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, nursing mothers, or women of reproductive ability who are unwilling to&#xD;
             use effective contraception or abstinence&#xD;
&#xD;
          -  Serum creatinine &gt; 1.6mg/dL&#xD;
&#xD;
          -  Creatinine clearance &lt; 75 ml/min&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &gt; 2.5 x upper limit of normal&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; 2.5 x upper limit of normal&#xD;
&#xD;
          -  Bilirubin &gt; 1.6 or international normalized ratio (INR) &gt; 1.5 due to hepatic&#xD;
             dysfunction&#xD;
&#xD;
          -  Albumin &lt; 3.0g/dL&#xD;
&#xD;
          -  Clinically significant pulmonary dysfunction, as determined by medical history and&#xD;
             physical exam; patients so identified will undergo pulmonary functions testing and&#xD;
             those with Forced expiratory volume in one second (FEV1) &lt; 80% predicted or diffusing&#xD;
             capacity of the lung for carbon monoxide (DLco) (corr for hemoglobin [Hgb]) &lt; 75% will&#xD;
             be excluded&#xD;
&#xD;
          -  Significant cardiovascular abnormalities as defined by any one of the following:&#xD;
             congestive heart failure, symptoms of coronary artery disease&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) metastases greater than 1 cm at time of&#xD;
             therapy; patients with 1-2 asymptomatic, less than 1cm brain/CNS metastases without&#xD;
             significant edema may be considered for treatment&#xD;
&#xD;
          -  Patients with active infections or oral temperature &gt; 38.2 C within 48 hours of study&#xD;
             entry or systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
          -  Chemotherapeutic agents (standard or experimental), radiation therapy, or other&#xD;
             immunosuppressive therapies less than 3 weeks prior to T cell therapy)&#xD;
&#xD;
          -  Concurrent treatment with steroids&#xD;
&#xD;
          -  Patients must not be receiving any other experimental drugs within 3 weeks of the&#xD;
             initiation of the protocol and must have recovered from all side effects of such&#xD;
             therapy&#xD;
&#xD;
          -  The following agents are not allowed while on study: systemic corticosteroids (except&#xD;
             as outlined for management of toxicity of nontransduced CTL), immunotherapy (for&#xD;
             example, interleukins, interferons, melanoma vaccines, intravenous immunoglobulin,&#xD;
             expanded polyclonal TIL or LAK therapy), pentoxifylline, or other investigational&#xD;
             agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <disposition_first_submitted>December 2, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 2, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 8, 2011</disposition_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sylvia Lee</investigator_full_name>
    <investigator_title>Research Associate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Denileukin diftitox</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

